Results 11 to 20 of about 6,730 (183)
Клиническая онкогематология, 2017 Background. New medications, thrombopoietin mimetics which were recently introduced into clinical practice allowed to achieve clinical response in patients with chronic glucocorticoid-resistant idiopathic thrombocytopenic purpura (ITP). However, the high
Vasilii Anatol’evich Shuvaev +3 more
doaj +1 more source
The biology of thrombopoietin and thrombopoietin receptor agonists [PDF]
International Journal of Hematology, 2013 Thrombopoietin (TPO) is the major physiological regulator of platelet production. TPO binds the TPO receptor, activates JAK and STAT pathways, thus stimulating megakaryocyte growth and platelet production. There is no "sensor" of the platelet count; rather TPO is produced in the liver at a constant rate and cleared by TPO receptors on platelets.
openaire +2 more sources
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Pharmacological Research, 2022 The Janus kinase (JAK) family of nonreceptor protein-tyrosine kinases consists of JAK1, JAK2, JAK3, and TYK2 (Tyrosine Kinase 2). Each of these proteins contains a JAK homology pseudokinase (JH2) domain that interacts with and regulates the activity of ...
Robert Roskoski, Jr.
doaj +1 more source
Effect of Thrombopoietin Receptor Agonist on Pregnant Mice [PDF]
Pharmaceutics, 2022 Thrombopoietin receptor agonists (TPO-RAs) are an effective treatment for refractory immune thrombocytopenia (ITP). However, the use of TPO-RAs is limited for ITP in pregnant women due to concerns about fetal toxicity. In this study, we examined the effects of romiplostim, one of the TPO-RAs, on pregnant mice. The mice were injected subcutaneously with
Kensaku Nakai +9 more
openaire +3 more sources
SOME THROMBOCYTE FACTORS DEVELOPMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C
Медицинский вестник Юга России, 2013 Purpose: to examine the frequency of mutations W 515K and W 515L in the Mpl, the encoder receptors platelets to thrombopoietin and determine the degree of activity of enzymes of blood platelets - glycogen, alpha-naphthylhesterase(αANАE) and adenosine ...
N. Y. Pshenichnaya, G. V. Kuznetsova
doaj +1 more source
Thrombopoietin receptor agonists in hereditary thrombocytopenias [PDF]
Journal of Thrombosis and Haemostasis, 2018 Hereditary thrombocytopenias (HTPs) constitute a heterogeneous group of diseases characterized by a reduction in platelet count and a potential bleeding risk. As a result of advances in diagnostic methods, HTPs are increasingly being identified, and appear to be less rare than previously thought.
Rodeghiero, F. +2 more
openaire +3 more sources
Haematologica, 2012 Background Thrombocytopenia with absent radii syndrome is defined by bilateral radius aplasia and thrombocytopenia. Due to impaired thrombopoietin signaling there are only few bone marrow megakaryocytes and these are immature; the resulting platelet ...
Janine Fiedler +9 more
doaj +1 more source
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. [PDF]
PLoS Medicine, 2006 The JAK2V617F allele has recently been identified in patients with polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis with myeloid metaplasia (MF).
Yana Pikman +16 more
doaj +1 more source
Clinical Indications for Thrombopoietin and Thrombopoietin-Receptor Agonists [PDF]
Transfusion Medicine and Hemotherapy, 2013 Thrombocytopenia is a common hematologic disorder. Stimulation of thrombopoiesis may reduce the risk for thrombocytopenia-induced bleeding, prevent severe thrombocytopenia, and reduce the need for platelet transfusion. The key cytokine is thrombopoietin (TPO).
openaire +2 more sources
Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia [PDF]
International Journal of Molecular Sciences, 2021 In the last decade, improvements in genetic testing have revolutionized the molecular diagnosis of inherited thrombocytopenias (ITs), increasing the spectrum of knowledge of these rare, complex and heterogeneous disorders. In contrast, the therapeutic management of ITs has not evolved in the same way.
José María Bastida +3 more
openaire +2 more sources